Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII\u2122","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) Exclusivity","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Tazarotene

    Menu

    Tazarotene

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cosette Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy...

              Details:

              Tazarotene-Generic (tazarotene) topical 0.1% cream is used to help reduce fine facial wrinkles and certain types of dark and light spots on the face in patients who use a total skin care program and avoid sunlight. Tazarotene topical cream and gel are used to treat psoriasis.

              Lead Product(s): Tazarotene

              Therapeutic Area: Dermatology Product Name: Tazarotene-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ortho Dermatologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference

              Details:

              ARAZLO® (tazarotene) Lotion, 0.045% is a prescription medicine used on the skin (topical) to treat people 9 years of age and older with acne, which can include blackheads, whiteheads, and other pimples.

              Lead Product(s): Tazarotene

              Therapeutic Area: Dermatology Product Name: Arazlo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bausch Health

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ortho Dermatologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference

              Details:

              The presentations will feature new efficacy and safety analyses of ARAZLO® (tazarotene) Lotion, 0.045%, long-term outcomes of DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, quality of life improvement with SILIQ® (brodalumab) injection.

              Lead Product(s): Halobetasol,Tazarotene

              Therapeutic Area: Dermatology Product Name: Duobrii

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bausch Health

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch Health

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII™

              Details:

              When administered together in DUOBRII, they provide complementary effects due to their individual modes of action targeting different receptors and pathways to achieve anti-inflammatory control and epidermal morphologic restoration.

              Lead Product(s): Halobetasol,Tazarotene

              Therapeutic Area: Dermatology Product Name: Duobrii

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY